Beneath the Surface: The Secret to Prexasertib’s Potential

Beneath the surface of Prexasertib’s clinical potential lies a complex and often overlooked story of molecular precision. Developed by Eli Lilly as a checkpoint kinase 1 and 2 (CHK1,2) inhibitor, Prexasertib operates through a finely tuned mechanism that disrupts tumor cell survival. By suppressing CHK1 and CHK2 activity, it downregulates Cdc25A, preventing cyclin-dependent kinase (CDC) […]